Since 2019, Biomay has operated exclusively as a CDMO and has positioned itself as a partner for manufacturing of plasmid DNA, messenger RNA, and recombinant protein for clients in the growing gene therapy field.

With the construction of a new plant in Vienna, Biomay is growing to a mid-sized CDMO.